News

The National Institutes for Health and Care Excellence (NICE) has approved polatuzumab vedotin for use on the NHS in people with diffuse large B-cell lymphoma (DLBCL).

Have your say on chlormethine gel for mycosis fungoides - consultation runs until 26 August.

The European Medicines Agency has approved acalabrutinib for chronic lymphocytic leukaemia (CLL).

Updated guidelines for the diagnosis and treatment of people with follicular lymphoma.

Brentuximab vedotin is to be available on the NHS for first-line treatment of anaplastic large cell lymphoma.

Acalabrutinib shows potential as a chemotherapy-free treatment option for people with CLL who have not been treated before.

The European Medicines Agency has approved brentuximab vedotin for first-line treatment of anaplastic large cell lymphoma.

Obinutuzumab plus bendamustine routinely available on the NHS for people with follicular lymphoma who have not responded to rituximab.

New European guidelines give evidence-based recommendations for the diagnosis, treatment and follow-up of people with marginal zone lymphoma.

NICE approves new, chemotherapy-free treatment option - lenalidomide in combination with rituximab.